AA
ACRS icon

ALPS Advisors’s Aclaris Therapeutics ACRS Stock Holding History

ALPS Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$750K Buy
141,749
+43,574
+44% +$194K ﹤0.01% 786
2026
Q1 		$368K Buy
98,175
+9,209
+10% +$31.1K ﹤0.01% 961
2025
Q4 		$268K Buy
+88,966
New +$225K ﹤0.01% 950
2025
Q2 		– Sell
-78,782
Closed -$121K – 1026
2025
Q1 		$121K Buy
78,782
+21,022
+36% +$44.8K ﹤0.01% 976
2024
Q4 		$143K Buy
+57,760
New +$144K ﹤0.01% 982
2023
Q4 		– Sell
-52,222
Closed -$358K – 961
2023
Q3 		$358K Buy
52,222
+269
+0.5% +$2.3K ﹤0.01% 646
2023
Q2 		$539K Buy
51,953
+8,017
+18% +$72.5K ﹤0.01% 600
2023
Q1 		$355K Sell
43,936
-1,269
-3% -$16.1K ﹤0.01% 672
2022
Q4 		$712K Buy
+45,205
New +$727K 0.01% 533
2018
Q4 		– Sell
-54,824
Closed -$796K – 871
2018
Q3 		$796K Buy
54,824
+9,977
+22% +$171K 0.01% 445
2018
Q2 		$896K Buy
44,847
+3,478
+8% +$64.3K 0.01% 357
2018
Q1 		$725K Buy
41,369
+7,201
+21% +$153K 0.01% 372
2017
Q4 		$843K Buy
34,168
+4,626
+16% +$113K 0.01% 293
2017
Q3 		$762K Buy
29,542
+5,413
+22% +$145K 0.01% 289
2017
Q2 		$654K Buy
24,129
+1,718
+8% +$46.7K ﹤0.01% 313
2017
Q1 		$668K Sell
22,411
-2,021
-8% -$58.3K ﹤0.01% 261
2016
Q4 		$663K Buy
+24,432
New +$623K ﹤0.01% 251

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

ALPS Advisors's ACRS Position: Q2 2026 in Review

ALPS Advisors increased its Aclaris Therapeutics (ACRS) stake by 44% in Q2 2026, buying an estimated $194K and bringing the position to 141,749 shares worth $750K. The position accounts for ﹤0.01% of the portfolio, ranked #786.

ALPS Advisors first reported a position in ACRS in Q4 2016 and has held it in 17 quarters since. The position peaked at $896K in Q2 2018. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • ALPS Advisors held 141,749 shares of Aclaris Therapeutics worth $750K as of Q2 2026.
  • ALPS Advisors bought 43,574 Aclaris Therapeutics shares in Q2 2026, an estimated $194K.
  • Aclaris Therapeutics made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #786 holding.
  • ALPS Advisors first reported a position in Aclaris Therapeutics in Q4 2016 and has held it in 17 quarters since.
  • ALPS Advisors's Aclaris Therapeutics position peaked at $896K in Q2 2018.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.